Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04648163
Other study ID # 29-607
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2017
Est. completion date September 1, 2018

Study information

Verified date November 2020
Source Medical University of Graz
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Postoperative complications like seroma formation and wound site infection readily occur following completion axillary lymph node dissection (ALND) for malignant melanoma. We analyzed the impact of time-to-drain removal and drainage volume on seroma formation after ALND.


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date September 1, 2018
Est. primary completion date May 1, 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - histologically confirmed malignant melanoma - underwent axillary lymph node dissection (level I-III) - daily drainage volume records over a two-week period available Exclusion Criteria: - daily drainage volume records over a two-week period not available

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Austria Medical University of Graz Graz Styria

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary daily drainage volume during hospitalization The daily drainage amount durin hospital stay through study completion, an average of 1 year
Primary total drainage volume during hospitalization The total drainage amount during hospital stay through study completion, an average of 1 year
Primary time-to-drain removal The timepoint when the drain was removed through study completion, an average of 1 year
Primary evacuation of seroma after drain removal If evacuation of seroma after drain removal was needed through study completion, an average of 1 year
Secondary demographic data - age age through study completion, an average of 1 year
Secondary demographic data - sex sex through study completion, an average of 1 year
Secondary demographic data - BMI body mass index (BMI) through study completion, an average of 1 year
Secondary demographic data - smoking smoking through study completion, an average of 1 year
Secondary demographic data - Diabetes mellitus diabetes mellitus through study completion, an average of 1 year
Secondary demographic data - allergies allergies through study completion, an average of 1 year
Secondary intraoperative parameters surgical procedure time through study completion, an average of 1 year
Secondary intraoperative parameters - site site through study completion, an average of 1 year
Secondary Amount of histologically analyzed lymph nodes The amount lymph nodes found at histological analysis through study completion, an average of 1 year
Secondary Surgical complications graded by the Clavien-Dindo-classification ( 1:normal postoperative cause without need of pharmacological treatment ; 2: pharmacological treatment ; 3: surgical, endoscooic or radiological treatment; 4: live-threating complications; 5: Death through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT04074096 - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Phase 2
Completed NCT02935790 - Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab Phase 1
Recruiting NCT05478876 - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract N/A
Completed NCT01211262 - Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Phase 1
Recruiting NCT03649529 - Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy Early Phase 1
Completed NCT03278665 - 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy Phase 1/Phase 2
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01455259 - Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors Phase 1/Phase 2
Completed NCT00978913 - Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00350597 - GM-CSF as Adjuvant Therapy of Melanoma Phase 2
Completed NCT00336986 - Efficacy Study of IL-21 to Treat Metastatic Melanoma Phase 2
Completed NCT02523313 - Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED Phase 2
Completed NCT03545334 - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study N/A
Completed NCT04253574 - Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
Completed NCT00179608 - Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy Phase 1
Terminated NCT00104884 - FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Phase 2